{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:07:34Z","timestamp":1792670854044,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40121-024-01098-8","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T13:21:51Z","timestamp":1738243311000},"page":"463-481","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Phase 3B, Open-Label Study to Evaluate the Immunogenicity and Safety of the Quadrivalent Meningococcal Nimenrix\u00ae Vaccine When Given to Healthy Infants at 3 and 12 Months of Age"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2078-8475","authenticated-orcid":false,"given":"Susanna","family":"Koski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9023-581X","authenticated-orcid":false,"given":"Federico","family":"Martinon-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5776-164X","authenticated-orcid":false,"given":"Mika","family":"R\u00e4met","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lefteris","family":"Zolotas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Maansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5302-5477","authenticated-orcid":false,"given":"Mark","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8958-1734","authenticated-orcid":false,"given":"Paula","family":"Peyrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5153-4043","authenticated-orcid":false,"given":"Jamie","family":"Findlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8188-1791","authenticated-orcid":false,"given":"Paul","family":"Balmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1246-530X","authenticated-orcid":false,"given":"Luis","family":"Jodar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6518-4547","authenticated-orcid":false,"given":"William C.","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6413-1718","authenticated-orcid":false,"given":"Annaliesa S.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0454-3515","authenticated-orcid":false,"given":"Johannes","family":"Beeslaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"1098_CR1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(06)67932-4","volume":"367","author":"MJ Thompson","year":"2006","unstructured":"Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367:397\u2013403.","journal-title":"Lancet"},{"key":"1098_CR2","doi-asserted-by":"crossref","unstructured":"Pardo de Santayana C, Tin Tin Htar M, Findlow J, Balmer P. Epidemiology of invasive meningococcal disease worldwide from 2010\u20132019: a literature review. Epidemiol Infect. 2023;151:e57.","DOI":"10.1017\/S0950268823000328"},{"key":"1098_CR3","doi-asserted-by":"crossref","unstructured":"Wang B, Santoreneos R, Giles L, Haji Ali Afzali H, Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine. 2019;37:2768\u201382.","DOI":"10.1016\/j.vaccine.2019.04.020"},{"key":"1098_CR4","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","volume":"7","author":"KJ Olbrich","year":"2018","unstructured":"Olbrich KJ, Muller D, Schumacher S, et al. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7:421\u201338.","journal-title":"Infect Dis Ther"},{"key":"1098_CR5","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/INF.0000000000000282","volume":"33","author":"C Stein-Zamir","year":"2014","unstructured":"Stein-Zamir C, Shoob H, Sokolov I, et al. The clinical features and long-term sequelae of invasive meningococcal disease in children. Pediatr Infect Dis J. 2014;33:777\u20139.","journal-title":"Pediatr Infect Dis J"},{"key":"1098_CR6","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1093\/cid\/civ028","volume":"60","author":"M Sadarangani","year":"2015","unstructured":"Sadarangani M, Scheifele DW, Halperin SA, et al. Outcomes of invasive meningococcal disease in adults and children in Canada between 2002 and 2011: a prospective cohort study. Clin Infect Dis. 2015;60:e27\u201335.","journal-title":"Clin Infect Dis"},{"key":"1098_CR7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12879-022-07129-4","volume":"22","author":"SS Voss","year":"2022","unstructured":"Voss SS, Nielsen J, Valentiner-Branth P. Risk of sequelae after invasive meningococcal disease. BMC Infect Dis. 2022;22:148.","journal-title":"BMC Infect Dis"},{"key":"1098_CR8","unstructured":"European Centre for Disease Prevention and Control. Surveillance Atlas of Infectious Diseases. https:\/\/atlas.ecdc.europa.eu\/public\/index.aspx. Accessed 28 June 2024."},{"key":"1098_CR9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/14760584.2024.2329618","volume":"23","author":"R Borrow","year":"2024","unstructured":"Borrow R, Findlow J. The important lessons lurking in the history of meningococcal epidemiology. Expert Rev Vaccines. 2024;23:445\u201362.","journal-title":"Expert Rev Vaccines"},{"key":"1098_CR10","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3390\/microorganisms8101521","volume":"8","author":"M Pizza","year":"2020","unstructured":"Pizza M, Bekkat-Berkani R, Rappuoli R. Vaccines against meningococcal diseases. Microorganisms. 2020;8:1521.","journal-title":"Microorganisms"},{"key":"1098_CR11","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1099\/0022-1317-51-9-717","volume":"51","author":"P Balmer","year":"2002","unstructured":"Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol. 2002;51:717\u201322.","journal-title":"J Med Microbiol"},{"key":"1098_CR12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","volume":"326","author":"ME Ramsay","year":"2003","unstructured":"Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ. 2003;326:365\u20136.","journal-title":"BMJ"},{"key":"1098_CR13","doi-asserted-by":"crossref","unstructured":"Tin Tin Htar M, Jackson S, Balmer P, et al. Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs. BMC Public Health. 2020;20:1890.","DOI":"10.1186\/s12889-020-09946-1"},{"key":"1098_CR14","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/527401","volume":"197","author":"MC Maiden","year":"2008","unstructured":"Maiden MC, Ibarz-Pavon AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197:737\u201343.","journal-title":"J Infect Dis"},{"key":"1098_CR15","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.vaccine.2016.02.014","volume":"34","author":"MM Mustapha","year":"2016","unstructured":"Mustapha MM, Marsh JW, Harrison LH. Global epidemiology of capsular group W meningococcal disease (1970\u20132015): multifocal emergence and persistence of hypervirulent sequence type (ST)-11 clonal complex. Vaccine. 2016;34:1515\u201323.","journal-title":"Vaccine"},{"key":"1098_CR16","unstructured":"Organizaci\u00f3n Panamericana de la Salud. Informe Regional de SIREVA II, 2018. https:\/\/iris.paho.org\/bitstream\/handle\/10665.2\/54567\/9789275324035_spa.pdf?sequence=1&isAllowed=y. Accessed 18 Dec 2023."},{"key":"1098_CR17","unstructured":"Annex I: summary of product characteristics (Nimenrix). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nimenrix-epar-product-information_en.pdf. Accessed 20 Sept 2023."},{"key":"1098_CR18","doi-asserted-by":"crossref","first-page":"7014","DOI":"10.1016\/j.vaccine.2022.09.077","volume":"40","author":"L Serra","year":"2022","unstructured":"Serra L, Webber C, Burman C, et al. Clinical trial and postmarketing safety experience with MenACWY-TT, a meningococcal group A, C, W, and Y tetanus conjugate vaccine. Vaccine. 2022;40:7014\u201321.","journal-title":"Vaccine"},{"key":"1098_CR19","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/cid\/ciab791","volume":"74","author":"M Ohm","year":"2022","unstructured":"Ohm M, Hahn\u00e9 SJM, van der Ende A, et al. Vaccine impact and effectiveness of meningococcal serogroup ACWY conjugate vaccine implementation in the Netherlands: a nationwide surveillance study. Clin Infect Dis. 2022;74:2173\u201380.","journal-title":"Clin Infect Dis"},{"key":"1098_CR20","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.vaccine.2021.11.075","volume":"40","author":"R Villena","year":"2022","unstructured":"Villena R, Valenzuela MT, Bastias M, Santolaya ME. Invasive meningococcal disease in Chile seven years after ACWY conjugate vaccine introduction. Vaccine. 2022;40:666\u201372.","journal-title":"Vaccine"},{"key":"1098_CR21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2352-4642(21)00335-7","volume":"6","author":"H Campbell","year":"2022","unstructured":"Campbell H, Andrews N, Parikh SR, et al. Impact of an adolescent meningococcal ACWY immunisation programme to control a national outbreak of group W meningococcal disease in England: a national surveillance and modelling study. Lancet Child Adolesc Health. 2022;6:96\u2013105.","journal-title":"Lancet Child Adolesc Health"},{"key":"1098_CR22","doi-asserted-by":"crossref","unstructured":"Villena R, Kriz P, Tin Tin Htar M, et al. Real-world impact and effectiveness of MenACWY-TT. Hum Vaccin Immunother. 2023;19:2251825.","DOI":"10.1080\/21645515.2023.2251825"},{"key":"1098_CR23","unstructured":"Package leaflet: Information for the user: NeisVac-C 0.5 ml suspension for injection in pre-filled syringe. https:\/\/www.hpra.ie\/img\/uploaded\/vaccines\/PIL_PA0822183001.pdf. Accessed 14 Dec 2023."},{"key":"1098_CR24","unstructured":"Minist\u00e9rio da Sa\u00fade (Governo Federal Brasil). Calend\u00e1rio nacional de vacina\u00e7\u00e3o da crian\u00e7a. https:\/\/www.gov.br\/saude\/pt-br\/vacinacao\/calendario. Accessed 14 Dec 2023."},{"key":"1098_CR25","unstructured":"European Centre for Disease Prevention and Control. Vaccine scheduler: vaccine schedules in all countries in the EU\/EEA. https:\/\/vaccine-schedule.ecdc.europa.eu\/. Accessed 14 Dec 2023."},{"key":"1098_CR26","unstructured":"Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda de Atenci\u00f3n Primaria. Calendarios de vacunaci\u00f3n espa\u00f1oles. https:\/\/www.aepap.org\/vacunas\/calendarios-espanoles. Accessed 28 Oct 2024."},{"key":"1098_CR27","unstructured":"European Centre for Disease Prevention and Control. Factsheet about meningococcal disease. https:\/\/www.ecdc.europa.eu\/en\/meningococcal-disease\/factsheet. Accessed 27 June 2024."},{"key":"1098_CR28","unstructured":"Annex I: summary of product characteristics (MenQuadfi). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/menquadfi-epar-product-information_en.pdf. Accessed 27 June 2024."},{"key":"1098_CR29","unstructured":"Minist\u00e8re du Travail de la Sant\u00e9 et des Solidarit\u00e9s. Calendrier des vaccinations et recommandations vaccinales 2024. https:\/\/sante.gouv.fr\/IMG\/pdf\/calendrier_vaccinal_avr2024.pdf. Accessed 27 June 2024."},{"key":"1098_CR30","unstructured":"Australian Government Department of Health and Aged Care. National Immunisation Program Schedule. https:\/\/www.health.gov.au\/topics\/immunisation\/when-to-get-vaccinated\/national-immunisation-program-schedule. Accessed 25 Jan 2024."},{"key":"1098_CR31","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1080\/21645515.2020.1794440","volume":"17","author":"PK Ghaswalla","year":"2021","unstructured":"Ghaswalla PK, D\u2019Angelo J, Abu-Elyazeed R. Rotavirus vaccination in the US: a systematic review of vaccination coverage and completion. Hum Vaccin Immunother. 2021;17:872\u20139.","journal-title":"Hum Vaccin Immunother"},{"key":"1098_CR32","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1080\/21645515.2018.1467200","volume":"14","author":"I Matthews","year":"2018","unstructured":"Matthews I, Dawson H. The impact of dosing schedules on the success of vaccination programmes in elderly populations: a summary of current evidence. Hum Vaccin Immunother. 2018;14:1957\u201362.","journal-title":"Hum Vaccin Immunother"},{"key":"1098_CR33","volume":"35","author":"J Wang","year":"2023","unstructured":"Wang J, Herweijer E, Nordqvist Kleppe S, et al. High coverage and adherence to dose intervals of the national school-based HPV vaccination program in Sweden during 2012\u20132019. Prev Med Rep. 2023;35: 102342.","journal-title":"Prev Med Rep"},{"key":"1098_CR34","unstructured":"European Medicines Agency. Assessment report (Nimenrix). https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/nimenrix-epar-public-assessment-report_en.pdf. Accessed 8 July 2024."},{"key":"1098_CR35","unstructured":"World Health Organization. Standardization and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A\/C vaccines. http:\/\/apps.who.int\/iris\/bitstream\/10665\/66298\/1\/WHO_V%26B_99.19.pdf. Accessed 10 Oct 2023."},{"key":"1098_CR36","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1080\/21645515.2019.1593082","volume":"15","author":"J Findlow","year":"2019","unstructured":"Findlow J, Balmer P, Borrow R. A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines. Hum Vaccin Immunother. 2019;15:2491\u2013500.","journal-title":"Hum Vaccin Immunother"},{"key":"1098_CR37","first-page":"780","volume":"10","author":"N Andrews","year":"2003","unstructured":"Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003;10:780\u20136.","journal-title":"Clin Diagn Lab Immunol"},{"key":"1098_CR38","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","volume":"23","author":"R Borrow","year":"2005","unstructured":"Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection\u2014serum bactericidal antibody activity. Vaccine. 2005;23:2222\u20137.","journal-title":"Vaccine"},{"key":"1098_CR39","doi-asserted-by":"crossref","unstructured":"Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129:1307\u201326.","DOI":"10.1084\/jem.129.6.1307"},{"key":"1098_CR40","unstructured":"US Food and Drug Administration. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. https:\/\/www.fda.gov\/media\/73679\/download. Accessed 1 Apr 2020."},{"key":"1098_CR41","unstructured":"MedDRA: medical dictionary for regulatory activities. https:\/\/www.meddra.org\/. Accessed 10 Apr 2023."},{"key":"1098_CR42","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1097\/INF.0000000000001484","volume":"36","author":"JM Merino Arribas","year":"2017","unstructured":"Merino Arribas JM, Carmona Martinez A, Horn M, et al. Safety and immunogenicity of the quadrivalent meningococcal serogroups A, C, W and Y tetanus toxoid conjugate vaccine coadministered with routine childhood vaccines in European infants: an open, randomized trial. Pediatr Infect Dis J. 2017;36:e98\u2013107.","journal-title":"Pediatr Infect Dis J"},{"key":"1098_CR43","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1016\/j.vaccine.2018.05.046","volume":"36","author":"G Dbaibo","year":"2018","unstructured":"Dbaibo G, Tinoco Favila JC, Traskine M, Jastorff A, Van der Wielen M. Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: a phase III, randomized study. Vaccine. 2018;36:4102\u201311.","journal-title":"Vaccine"},{"key":"1098_CR44","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/INF.0b013e31828693c5","volume":"32","author":"NP Klein","year":"2013","unstructured":"Klein NP, Baine Y, Bianco V, et al. One or two doses of quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old children. Pediatr Infect Dis J. 2013;32:760\u20137.","journal-title":"Pediatr Infect Dis J"},{"key":"1098_CR45","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.vaccine.2011.10.068","volume":"30","author":"CJ Gill","year":"2011","unstructured":"Gill CJ, Ram S, Welsch JA, Detora L, Anemona A. Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source. Vaccine. 2011;30:29\u201334.","journal-title":"Vaccine"},{"key":"1098_CR46","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12325-013-0032-5","volume":"30","author":"H Findlow","year":"2013","unstructured":"Findlow H, Borrow R. Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT. Adv Ther. 2013;30:431\u201358.","journal-title":"Adv Ther"},{"key":"1098_CR47","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.vaccine.2018.02.013","volume":"36","author":"CL Cutland","year":"2018","unstructured":"Cutland CL, Nolan T, Halperin SA, et al. Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: a phase III, open-label, randomised study. Vaccine. 2018;36:1908\u201316.","journal-title":"Vaccine"},{"key":"1098_CR48","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.trivac.2014.06.003","volume":"3","author":"T Vesikari","year":"2014","unstructured":"Vesikari T, Forsten A, Bianco V, Van der Wielen M, Miller JM. Antibody persistence to meningococcal serogroups A, C, W and Y in toddlers two years after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate (MenACWY-TT) vaccine as measured by bactericidal antibody assays using rabbit or human complement. Trials Vaccinol. 2014;3:121\u20136.","journal-title":"Trials Vaccinol"},{"key":"1098_CR49","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.4161\/hv.22166","volume":"8","author":"T Vesikari","year":"2012","unstructured":"Vesikari T, Forsten A, Boutriau D, et al. Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers. Hum Vaccin Immunother. 2012;8:1892\u2013903.","journal-title":"Hum Vaccin Immunother"},{"key":"1098_CR50","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.vaccine.2022.11.048","volume":"41","author":"CL Cutland","year":"2023","unstructured":"Cutland CL, Peyrani P, Webber C, et al. A phase 3, randomized, controlled, open-label study to evaluate the persistence up to 5 years of 1 or 2 doses of meningococcal conjugate vaccine MenACWY-TT given with or without 13-valent pneumococcal conjugate vaccine in 12\u201314-month-old children. Vaccine. 2023;41:1153\u201360.","journal-title":"Vaccine"},{"key":"1098_CR51","doi-asserted-by":"crossref","first-page":"7542","DOI":"10.1016\/j.vaccine.2020.09.050","volume":"38","author":"A Biolchi","year":"2020","unstructured":"Biolchi A, De Angelis G, Moschioni M, et al. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates. Vaccine. 2020;38:7542\u201350.","journal-title":"Vaccine"},{"key":"1098_CR52","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1080\/21645515.2020.1855951","volume":"17","author":"C Fazio","year":"2021","unstructured":"Fazio C, Biolchi A, Neri A, et al. Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy. Hum Vaccin Immunother. 2021;17:2225\u201331.","journal-title":"Hum Vaccin Immunother"},{"key":"1098_CR53","doi-asserted-by":"crossref","first-page":"e1661","DOI":"10.1093\/cid\/ciaa1244","volume":"73","author":"SN Ladhani","year":"2021","unstructured":"Ladhani SN, Campbell H, Andrews N, et al. First real-world evidence of meningococcal group B vaccine, 4CMenB, protection against meningococcal group W disease: Prospective Enhanced National Surveillance, England. Clin Infect Dis. 2021;73:e1661\u20138.","journal-title":"Clin Infect Dis"},{"key":"1098_CR54","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/INF.0000000000001123","volume":"35","author":"NP Klein","year":"2016","unstructured":"Klein NP, Baine Y, Kolhe D, et al. Five-year antibody persistence and booster response after 1 or 2 doses of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in healthy children. Pediatr Infect Dis J. 2016;35:662\u201372.","journal-title":"Pediatr Infect Dis J"},{"key":"1098_CR55","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1080\/21645515.2020.1746110","volume":"16","author":"T Vesikari","year":"2020","unstructured":"Vesikari T, Peyrani P, Webber C, et al. Ten-year antibody persistence and booster response to MenACWY-TT vaccine after primary vaccination at 1\u201310 years of age. Hum Vaccin Immunother. 2020;16:1280\u201391.","journal-title":"Hum Vaccin Immunother"},{"key":"1098_CR56","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1016\/j.vaccine.2011.03.043","volume":"29","author":"T Vesikari","year":"2011","unstructured":"Vesikari T, Karvonen A, Bianco V, Van der Wielen M, Miller J. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: an open, randomized controlled trial. Vaccine. 2011;29:4274\u201384.","journal-title":"Vaccine"},{"key":"1098_CR57","doi-asserted-by":"crossref","first-page":"e298","DOI":"10.1097\/INF.0000000000000897","volume":"34","author":"T Vesikari","year":"2015","unstructured":"Vesikari T, Forsten A, Bianco V, Van der Wielen M, Miller JM. Immunogenicity, safety and antibody persistence of a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine compared with monovalent meningococcal serogroup C vaccine administered four years after primary vaccination using the same vaccines. Pediatr Infect Dis J. 2015;34:e298-307.","journal-title":"Pediatr Infect Dis J"},{"key":"1098_CR58","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1007\/s10096-020-03914-8","volume":"39","author":"D Pace","year":"2020","unstructured":"Pace D, Gauci C, Barbara C. The epidemiology of invasive meningococcal disease and the utility of vaccination in Malta. Eur J Clin Microbiol Infect Dis. 2020;39:1885\u201397.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1098_CR59","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jadohealth.2024.01.016","volume":"74","author":"J Presa","year":"2024","unstructured":"Presa J, Findlow J, Zimet GD. Meningococcal vaccination of adolescents in the United States: past successes and future considerations. J Adolesc Health. 2024;74:1068\u201377.","journal-title":"J Adolesc Health"},{"key":"1098_CR60","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3390\/vaccines11050940","volume":"11","author":"K Schley","year":"2023","unstructured":"Schley K, Kowalik JC, Sullivan SM, et al. Assessing the role of infant and toddler MenACWY immunisation in the UK: does the adolescent MenACWY programme provide sufficient protection? Vaccines (Basel). 2023;11:940.","journal-title":"Vaccines (Basel)"},{"key":"1098_CR61","unstructured":"Menveo (meningococcal group A, C, W-135 and Y conjugate vaccine). Full prescribing information, GSK Vaccines S.r.l., Sovicille, Italy."},{"key":"1098_CR62","unstructured":"Menactra (meningococcal [groups A, C, Y and W-135] polysaccharide diphtheria toxoid conjugate vaccine). Full Prescribing Information, Sanofi Pasteur Inc, Swiftwater, PA."},{"key":"1098_CR63","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s40121-021-00467-x","volume":"10","author":"S Badur","year":"2021","unstructured":"Badur S, Al Dabbagh MA, Shibl AM, et al. The epidemiology of invasive meningococcal disease in the Kingdom of Saudi Arabia: a narrative review with updated analysis. Infect Dis Ther. 2021;10:2035\u201349.","journal-title":"Infect Dis Ther"},{"key":"1098_CR64","doi-asserted-by":"crossref","unstructured":"Shibl A, Tufenkeji H, Khalil M, Memish Z, Meningococcal Leadership Forum Expert Group. Consensus recommendation for meningococcal disease prevention for Hajj and Umra pilgrimage\/travel medicine. East Mediterr Health J. 2013;19:389\u201392.","DOI":"10.26719\/2013.19.4.389"},{"key":"1098_CR65","unstructured":"Kingdom of Saudia Arabia Ministry of Health. National immunization schedule. https:\/\/www.moh.gov.sa\/en\/HealthAwareness\/EducationalContent\/HealthTips\/Documents\/Immunization-Schedule.pdf. Accessed 16 Aug 2024."},{"key":"1098_CR66","doi-asserted-by":"crossref","first-page":"6","DOI":"10.15585\/mmwr.mm7301a2","volume":"73","author":"AP Wodi","year":"2024","unstructured":"Wodi AP, Murthy N, McNally VV, Daley MF, Cineas S. Advisory Committee on Immunization practices recommended immunization schedule for children and adolescents aged 18 years or younger\u2014United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73:6\u201310.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1098_CR67","unstructured":"European Medicines Agency. Assessment report: Nimenrix. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/nimenrix-h-c-2226-ii-0049-epar-assessment-report-variation_en.pdf. Accessed 24 July 2024."},{"key":"1098_CR68","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2393","volume":"338","author":"JA Sterne","year":"2009","unstructured":"Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338: b2393.","journal-title":"BMJ"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01098-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-024-01098-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01098-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T17:57:01Z","timestamp":1739642221000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-024-01098-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1098"],"URL":"https:\/\/doi.org\/10.1007\/s40121-024-01098-8","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Susanna Koski and Federico Martinon-Torres acted as principal investigators for the study reported in this manuscript, which was sponsored by Pfizer. Susanna Koski and Mika R\u00e4met are employees of Finnish Vaccine Research (FVR), which conducts clinical vaccine studies for many major vaccine manufacturers, including Pfizer. Federico Martinon-Torres has acted as principal investigator for other studies sponsored by Abbot, Cubist, GlaxoSmithKline, Janssen, Medimmune, MSD, Novavax, Novartis, Pfizer, Regeneron, Roche, Sanofi Pasteur, and Seqirus, with honoraria paid to his institution; and has consulting or advisory relationships with GlaxoSmithKline, Janssen, MSD, Pfizer, Sanofi Pasteur, and Seqirus. All other authors are current or former employees of Pfizer and may hold stock or stock options in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with consensus ethical principles derived from international guidelines, including the Declaration of Helsinki and Council for International Organizations of Medical Sciences Ethical Guidelines, applicable International Conference on Harmonisation Good Clinical Practice guidelines, and applicable laws and regulations. The protocol and related documents were reviewed and approved by the Ethics Committee Hospital District of Southwest Finland (study sites in Finland; reference number 7\/1800\/2021), Komisja Bioetyczna przy Okregowej Izbie Lekarskiej w Krakowie (Poland; reference number 11\/KBL\/OIL\/2021), and Comit\u00e9 de \u00c9tica de Investigaci\u00f3n con Medicamentos del Hospital Universitario 12 de Octubre (Spain; reference number 21\/040) before study initiation. A parent or legal guardian of each study participant provided written informed consent before the participant was enrolled.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}